Fall Covid shot rollout gets off to a bumpy start as some patients see insurance delays

Fall Covid shot rollout gets off to a bumpy start as some patients see insurance delays


Pharmacist Ani Martirosyan administers an immunization to a patient at a CVS on Tuesday, Sept. 12, 2023 in Glendale, CA.

Brian Van Der Brug | Los Angeles Times | Getty Images

The rollout of a new round of Covid vaccines in the U.S. is off to a bumpy start as some patients report delays in health insurance coverage for the shots. 

Private insurance plans and government payers such as Medicare are required to cover the new jabs from Pfizer and Moderna, which became available late last week. U.S. regulators have recommended all Americans ages 6 months and up get the new round of vaccines. 

The Centers for Medicare and Medicaid Services, some private health care providers and CVS confirmed the temporary delays in coverage and emphasized that Americans can access Covid vaccines at no cost through insurance plans. They said the reason for the delays is that some insurers are still working to update their plans to include the new vaccines.

Dozens of posts on social media in recent days show some patients were charged anywhere between $125 and $190 for a shot at pharmacies. Others were told their insurance plans aren’t covering the new vaccines yet. 

The reports are fueling confusion among insured patients about whether they can still access Covid shots for free – even after public health officials have reassured them that they can — just as cases tick up across the country.

It also comes after a huge shift in how Covid vaccines are covered in the U.S.

The government is shifting shots to the commercial market, which means manufacturers will sell their new jabs directly to health care providers at more than $120 per dose. Previously, the federal government purchased Covid vaccines directly from manufacturers at a discount to distribute to all Americans for free.

A CMS spokesperson said the agency is “aware that some consumers have had difficulty accessing COVID-19 vaccines, including experiencing unexpected insurance coverage denials at the point of service.”

CMS has been in “close contact with the plans about these transitions for months,” and is reaching out again to ensure that their systems are “up-to-date and prepared to meet their obligations to provide coverage of Covid-19 vaccines for participants, beneficiaries, and enrollees,” according to the spokesperson. 

A spokesperson for CVS told CNBC that some payers “are still updating their systems and may not yet be set up to cover the updated COVID-19 vaccines.” They added that the company’s pharmacy teams can help patients schedule a vaccine appointment for a later date if their coverage is denied. 

Sarah Lindsey, an owner of a Florida-based jewelry store, called on her own insurer to add the new Covid shots to its formulary. 

“Any insured member trying to get it at a pharmacy is being told it’s not approved and will cost $155. There’s no excuse for this,” she wrote Monday in a post on X, tagging Florida Blue, a local Blue Cross Blue Shield insurer. 

A spokesperson for Florida Blue said a “small percentage” of patients experienced issues with coverage, but the insurer does cover the shots for most beneficiaries at no cost. Any insured patients who were charged for a Covid shot should contact their pharmacy for reimbursement or file a claim with Florida Blue.

Meanwhile, a spokesperson for health care provider Elevance Health urged pharmacies to resubmit Covid vaccine claims “so they can be processed at a $0 copay.” They added that they expect the delays in coverage to be resolved quickly.

The coverage missteps come amid concerns that a mix of pandemic fatigue, the belief that Covid is “over” and confusion over personal risk levels will hinder the uptake of the new vaccines, which are designed to target the omicron subvariant XBB.1.5. 

Only 17% of the U.S. population — around 56 million people — have received Pfizer and Moderna’s bivalent Covid boosters since they were approved last September, according to the Centers for Disease Control and Prevention. 





Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More